Deferoxamine for Spontaneous Intracranial Hemorrhage: A Pilot Study on Neurological and Radiological Outcomes.

Q3 Medicine
Korean Journal of Neurotrauma Pub Date : 2025-04-14 eCollection Date: 2025-04-01 DOI:10.13004/kjnt.2025.21.e9
Mohammad Shirani, Masoud Sohrabiasl, Ali Meshkini, Farhad Mirzaei, Seyed Mohammad Mehdi Hashemi, Fatemeh Jafari, Ali Salami, Ebrahim Rafiei, Arad Iranmehr
{"title":"Deferoxamine for Spontaneous Intracranial Hemorrhage: A Pilot Study on Neurological and Radiological Outcomes.","authors":"Mohammad Shirani, Masoud Sohrabiasl, Ali Meshkini, Farhad Mirzaei, Seyed Mohammad Mehdi Hashemi, Fatemeh Jafari, Ali Salami, Ebrahim Rafiei, Arad Iranmehr","doi":"10.13004/kjnt.2025.21.e9","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>Spontaneous intracranial hemorrhage (ICH) is a catastrophic medical condition associated with significant morbidity and mortality. Because the accumulation of unbound iron following ICH contributes to secondary brain injury, deferoxamine, an approved chelation drug, has become the center of attention. However, its therapeutic effects remain a matter of dispute. This double-blind randomized controlled trial aimed to investigate the therapeutic potential of deferoxamine in terms of neurological and radiological outcomes.</p><p><strong>Methods: </strong>The study enrolled 42 participants diagnosed with spontaneous ICH, confirmed by computed tomography, and randomly assigned them to either a deferoxamine treatment group or the placebo control group. The placebo control group received routine treatment plus a placebo, whereas the treatment group received routine treatment conjugated with 7.5 mg/kg of deferoxamine per hour intravenously over the first 3 days. The study compared the hematoma and edema volumes, Glasgow coma scale (GCS) scores, and mortality rates between the 2 groups. Our study employed rigorous randomization and blinding procedures to ensure unbiased results.</p><p><strong>Results: </strong>There was a significant (<i>p</i><0.05) improvement in the patients' GCS scores until the fourth day; however, no significant difference was noted thereafter. In addition, both the edema and hematoma volumes were significantly lower in the deferoxamine treatment group versus the placebo control group, as were the length of stay, intubation requirement, and mortality.</p><p><strong>Conclusion: </strong>Deferoxamine administration can, at least within a short timeframe, improve neurological and radiological parameters.</p>","PeriodicalId":36879,"journal":{"name":"Korean Journal of Neurotrauma","volume":"21 2","pages":"124-136"},"PeriodicalIF":0.0000,"publicationDate":"2025-04-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12062813/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Korean Journal of Neurotrauma","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.13004/kjnt.2025.21.e9","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/4/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Objective: Spontaneous intracranial hemorrhage (ICH) is a catastrophic medical condition associated with significant morbidity and mortality. Because the accumulation of unbound iron following ICH contributes to secondary brain injury, deferoxamine, an approved chelation drug, has become the center of attention. However, its therapeutic effects remain a matter of dispute. This double-blind randomized controlled trial aimed to investigate the therapeutic potential of deferoxamine in terms of neurological and radiological outcomes.

Methods: The study enrolled 42 participants diagnosed with spontaneous ICH, confirmed by computed tomography, and randomly assigned them to either a deferoxamine treatment group or the placebo control group. The placebo control group received routine treatment plus a placebo, whereas the treatment group received routine treatment conjugated with 7.5 mg/kg of deferoxamine per hour intravenously over the first 3 days. The study compared the hematoma and edema volumes, Glasgow coma scale (GCS) scores, and mortality rates between the 2 groups. Our study employed rigorous randomization and blinding procedures to ensure unbiased results.

Results: There was a significant (p<0.05) improvement in the patients' GCS scores until the fourth day; however, no significant difference was noted thereafter. In addition, both the edema and hematoma volumes were significantly lower in the deferoxamine treatment group versus the placebo control group, as were the length of stay, intubation requirement, and mortality.

Conclusion: Deferoxamine administration can, at least within a short timeframe, improve neurological and radiological parameters.

去铁胺治疗自发性颅内出血:神经学和放射学结果的初步研究。
目的:自发性颅内出血(ICH)是一种灾难性的医学疾病,具有很高的发病率和死亡率。由于脑出血后未结合铁的积累会导致继发性脑损伤,去铁胺作为一种获批的螯合药物,已成为人们关注的焦点。然而,其治疗效果仍有争议。这项双盲随机对照试验旨在研究去铁胺在神经学和放射学方面的治疗潜力。方法:该研究招募了42名被诊断为自发性脑出血并经计算机断层扫描证实的参与者,并将他们随机分配到去铁胺治疗组或安慰剂对照组。安慰剂对照组接受常规治疗加安慰剂,而治疗组在前3天内接受常规治疗,每小时静脉注射7.5 mg/kg去铁胺。研究比较了两组患者的血肿和水肿体积、格拉斯哥昏迷评分(GCS)和死亡率。我们的研究采用严格的随机化和盲法程序,以确保结果公正。结论:去铁胺至少在短时间内可改善神经学和影像学指标。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
1.10
自引率
0.00%
发文量
41
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信